Industry ranking
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Apr 2020 - 30 Sept 2020 | 09 Feb 2021 | 56 | 14% | 48% | 38% | 54% |
| 01 Apr 2019 - 30 Sept 2019 | 01 Nov 2019 | 58 | 12% | 47% | 41% | 63% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
The company's standard payment terms are 60 days from date of invoice
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
If the supplier does not accept our standard payment terms our policy is to pay undisputed invoices within 7 days following the invoice due date
Maximum contractual payment period agreed
120
If the supplier does not agree to our standard payments terms our policy is to pay undisputed invoices within 7 days following the invoice due date.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Sterling Pharma Solutions Limited, registered in England as company number 05712796 and based in Cramlington, Northumberland, is a contract development and manufacturing organisation for the pharmaceutical industry. It develops and manufactures active pharmaceutical ingredients (APIs), antibody-drug conjugates (ADCs) and peptides, supporting projects from early discovery and preclinical work through clinical trials to full commercial cGMP manufacture. Its services span route scouting, process optimisation, hazardous and high potency chemistry, and controlled substances. The company operates facilities in Cramlington and Deeside in the UK, alongside sites in Ireland and the United States, serving biotech and pharmaceutical companies globally. It describes itself as a partnership development and manufacturing organisation (PDMO), emphasising scientific collaboration with customers throughout the pharmaceutical product lifecycle.
Generated from the company's website and Companies House records. Sources: sterlingpharmasolutions.com · sterlingpharmasolutions.com